NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

August 15, 2020

Study Completion Date

August 25, 2021

Conditions

Non Small Cell Lung CancerMetastasisRecurrence

Interventions

DRUG

Pembrolizumab

Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).

DRUG

Idelalisib

Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).

Trial Locations (1)

30912

Georgia Cancer Center at Augusta University, Augusta